Lazard Asset Management
TSHA icon

Lazard Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Lazard Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-154
Closed – – 2582
2024
Q4 		$0 Hold
154
– – ﹤0.01% 2546
2024
Q3 		$0 Sell
154
-212
-58% -$465 ﹤0.01% 2459
2024
Q2 		$0 Sell
366
-5,438
-94% -$15.8K ﹤0.01% 2431
2024
Q1 		$16K Sell
5,804
-3,001
-34% -$6.25K ﹤0.01% 1857
2023
Q4 		$15K Buy
+8,805
New +$17.6K ﹤0.01% 2077

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lazard Asset Management's TSHA Position: Q1 2025 in Review

Lazard Asset Management sold out of Taysha Gene Therapies (TSHA) in Q1 2025, closing a stake of 154 shares.

Lazard Asset Management first reported a position in TSHA in Q4 2023 and held it in 5 quarters. The position peaked at $16K in Q1 2024. 127 funds tracked by Wall St. Rank hold TSHA as of Q1 2025.

  • Lazard Asset Management reported no remaining Taysha Gene Therapies position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 154 Taysha Gene Therapies shares in Q1 2025.
  • Lazard Asset Management first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 5 quarters.
  • Lazard Asset Management's Taysha Gene Therapies position peaked at $16K in Q1 2024.
  • 127 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.